Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
A live, multi-source view of Neurocrine Biosciences, Inc. (NBIX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 2,500 employees · neurocrine.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Neurocrine Biosciences, Inc. (NBIX) had a market capitalization of $15.82B, a trailing P/E of 22.8 (forward 13.0) and a beta of 0.38; the shares traded in a 52-week range of $122.14 – $186.12 (8.2% over the year).
- Market cap
- $15.82B
- Enterprise value
- $15.89B
- Trailing P/E
- 22.8
- Forward P/E
- 13.0
- PEG ratio
- 0.32
- Price / book
- 4.28
- EPS (trailing)
- $6.83
- EPS (forward)
- $11.97
- Payout ratio
- 0.0%
- Ex-dividend date
- 1995-12-29
- 52-week range
- $122.14 – $186.12
- 52-week change
- 8.2%
- Beta
- 0.38
- Average volume
- 1.2M
- Shares outstanding
- 101.6M
- Short % of float
- 5.81%
- Profit margin
- 20.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Neurocrine Biosciences, Inc. (NBIX) last closed at $156.57 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price +1.2% versus its 20-day average, 20-day versus 50-day average spread -6.2%, MACD histogram 0.70.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 47 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of NBIX; corporate insiders filed 0 buys and 2 sells (2 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Eric Benevich (0B/1S), Leslie Norwalk V (0B/1S). Who is trading what
RapidTradeView pick record
NBIX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Neurocrine Biosciences, Inc. (NBIX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell NBIX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.